MIST
Milestone Pharmaceuticals Surges into New Era with FDA Approval of CARDAMYST
Milestone Pharmaceuticals, a leading pharmaceutical company, marked a significant milestone in its journey by securing FDA approval for CARDAMYST, an etripamil nasal spray for paroxysmal supraventricular tachycardia (PSVT), also known as the conversion of PSVT to normal sinus rhythm in adults. The approval, announced in December 2025, represents a transformative